Navigation Links
Catabasis Closes $32.4 Million Series B Financing
Date:11/14/2013

CAMBRIDGE, Mass., Nov. 15, 2013 /PRNewswire/ -- Catabasis Pharmaceuticals, Inc., today announced it has completed a $32.4 million Series B financing round led by new investor Lightstone Ventures. A leading public crossover fund and all current Catabasis investors, including SV Life Sciences, Clarus Ventures, MedImmune Ventures and Advanced Technology Ventures, also participated in the financing.

"This investment reflects our confidence in Catabasis' pipeline of SMART Linker conjugates as much as our belief in management's ability to successfully advance its clinical candidates," said Jean George, partner of Lightstone Ventures. "Catabasis has achieved a number of important milestones in the past year including positive data from Phase 1 studies of both CAT-2003 and CAT-1004. We look forward to working with the management team as they complete the ongoing Phase 2 trial for CAT-2003 and seek to advance the rest of the pipeline."

Catabasis plans to use proceeds from this financing to support the development of its lead compound, CAT-2003, a modulator of the lipid synthesis pathway, which is currently in a Phase 2 clinical trial in patients with hypertriglyceridemia and in combination with statins in patients with hypercholesterolemia. Catabasis also plans to use the proceeds to support the continued clinical and pre-clinical development of other SMART Linker conjugates in the pipeline.

"We are tremendously excited about the progress we've made with our pipeline thus far, having reported positive Phase 1 data for both CAT-2003 and CAT-1004 and having advanced CAT-2003 to Phase 2," said Jill Milne, Ph.D., co-founder and chief executive officer of Catabasis. "This financing enables Catabasis to continue to execute on the promise of its pipeline for dyslipidemias and diseases involving chronic inflammation."  '/>"/>

SOURCE Catabasis Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Catabasis Initiates Phase 1 Trial of CAT-2003 for Treatment of Severe Hypertriglyceridemia
2. Catabasis Pharmaceuticals Announces Issuance of Patents for CAT-1000 and CAT-2000 Series
3. Catabasis Names Ian Sanderson Chief Financial Officer
4. Independa Closes Convertible Note Funding at $2.35 Million
5. Stereotaxis Closes $18.5 Million Private Placement Financings
6. Boston Scientific Closes Cameron Health Acquisition
7. C8 MediSensors Closes $19 million Preferred Stock Financing
8. Igenica Closes $33 Million in Series C Funding
9. BONESUPPORT Closes Second Tranche of Funding
10. PTC Therapeutics Closes $30 Million Financing
11. Chiasma Closes $38.5 Million Equity Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... 10, 2014  Valeant Pharmaceuticals International, Inc. (NYSE: ... has completed the sale to Galderma of all rights ... held by Valeant for $1.4 billion in cash, pursuant ... recently completed its acquisition of Galderma. ... products to a company that is firmly committed to ...
(Date:7/10/2014)... , July 10, 2014   LabStyle Innovations ... Solution, today announced the appointment of Professor ... of its Board of Directors. Prof. ... business experience to LabStyle as an entrepreneur, venture ... and corporate governance expert. He currently serves on ...
(Date:1/15/2014)... N.Y. , Jan. 15, 2014 Sono-Tek Corporation (OTC ... months ended November 30, 2013, compared to sales of $2,202,000 ... 20%. Once again, this quarter has also shown growth over ... the first quarter of this fiscal year. Markets that experienced ...
Breaking Medicine Technology:LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 2LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 3LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 4Sono-Tek Announces Third Quarter Results 2Sono-Tek Announces Third Quarter Results 3Sono-Tek Announces Third Quarter Results 4
... Pa., Sept. 9 DeVilbiss Healthcare has selected Business ... the successful implementation of its Microsoft Dynamics AX solution. ... Sunrise Medical, DeVilbiss sought to select and implement a ... successful medical device manufacturer. The primary ...
... Sept. 9 Diplomat Specialty Pharmacy announced today they have earned ... ranking of the fastest-growing private companies in America. "We,re ... earning a position of 554 in the nation, but if you ... are even more remarkable," stated Phil Hagerman, President and CEO of ...
Cached Medicine Technology:Business & Decision North America Announces the Successful Go-Live of Microsoft Dynamics AX at DeVilbiss Healthcare 2Diplomat Specialty Pharmacy Honored by Inc. Magazine as One of the Nation's Fastest-Growing Companies 2
(Date:7/12/2014)... Praeclarus Press is excited to ... new resource for women in need of lactation support. ... away from their children. Today’s mothers receive very clear ... but often feel unsupported when it comes to balancing ... evidence-based insights, and written by Nancy Mohrbacher, an international ...
(Date:7/12/2014)... 2014 Floor-grade instrument ... out of 5. This above-average score represents favorable ... buyer negotiation power over the three years to ... “during the period, surging demand for healthcare services ... new product development, have placed upward pressure on ...
(Date:7/12/2014)... (PRWEB) July 12, 2014 Ladies, it doesn't ... out there. Those who are looking for an affordable gown ... women’s special occasion dresses) to get their dream items. Recently, ... and tea length gowns . Along with that, it is ... can enjoy the special offer; the deadline of this promotion ...
(Date:7/11/2014)... The American Association of Poison Control Centers and ... Senator Bill Nelson (D-FL) for his introduction of the ... 10, 2014. Along with fellow Senate co-sponsors, this bill ... enact rules requiring safer, child-resistant packaging for any liquid ... of the bill include: Sen. Richard Blumenthal (D-CT), Sen. ...
(Date:7/11/2014)... York, New York (PRWEB) July 11, 2014 ... http://www.transvaginalmeshlawsuithelp.com/ ) , filed against Johnson & Johnson’s ... courts, Bernstein Liebhard LLP notes that the Texas ... investigating the company’s marketing of surgical mesh products ... urinary incontinence. According to a report from kens5.com, ...
Breaking Medicine News(10 mins):Health News:Praeclarus Press Announces the Release of Working and Breastfeeding Made Simple by Nancy Mohrbacher, A Much Needed Resource For Today's Working Mothers 2Health News:Floor-Grade Instruments Procurement Category Market Research Report from IBISWorld has Been Updated 2Health News:Floor-Grade Instruments Procurement Category Market Research Report from IBISWorld has Been Updated 3Health News:Floor-Grade Instruments Procurement Category Market Research Report from IBISWorld has Been Updated 4Health News:Worldwide Brides-to-be: It Is Time To Show Your Beauty By Wearing A Trendy Summer Short Wedding Dress From Discount-Dress.com 2Health News:AAPCC Issues Statement on the Introduction of the Child Nicotine Poison Prevention Act of 2014 2Health News:AAPCC Issues Statement on the Introduction of the Child Nicotine Poison Prevention Act of 2014 3Health News:Transvaginal Mesh Lawsuit News: Bernstein Liebhard LLP Notes Report of Texas Probe into Ethicon Pelvic Mesh Marketing 2Health News:Transvaginal Mesh Lawsuit News: Bernstein Liebhard LLP Notes Report of Texas Probe into Ethicon Pelvic Mesh Marketing 3Health News:Transvaginal Mesh Lawsuit News: Bernstein Liebhard LLP Notes Report of Texas Probe into Ethicon Pelvic Mesh Marketing 4
... ... Honorees were Named, FRANKLIN LAKES, N.J., April 1, 2008 At ... on,Monday night, Anthony Welters, Dr. June E. Osborn and Dr. Nelson L. ... Distinguished Alumni Award, respectively., The event was held at the Union ...
... gone from an art form that largely warned against the ... drug use, according to the first systematic social science study ... is published in the April 2008 issue of Addiction Research ... drug use have increased over time, and drug references increased ...
... body fat, leaving them prone to heart disease, diabetes ... to the contrary, more than half of normal-weight Americans ... their overweight contemporaries, this makes them susceptible to heart ... says. , Men whose body fat is greater than ...
... Hundreds of Hopefuls Participating in National Casting Call ... ... In celebration of Earth Month,Whole Foods Market, the world,s ... eco-conscious,personalities were chosen from hundreds of entries to host its ...
... Fla., April 1, 2008 Valensa International,introduced ... this,year,s Natural Products Expo West Conference. This ... the,historically known benefits of cranberry with D-mannose, ... the Larch tree. The,product is available in ...
... Dispute Resolution Process is ... Expeditious Path to Final Approval -, LAVAL, QC, ... today announced that it has appealed the U.S. Food ... to,the next supervisory level under the FDA,s Formal Dispute ...
Cached Medicine News:Health News:The Changing Face of Medicine: National Medical Fellowships Annual Awards Gala Honors Three Fellows 2Health News:The Changing Face of Medicine: National Medical Fellowships Annual Awards Gala Honors Three Fellows 3Health News:Drug use increasingly glamorized in rap music, according to new study of 2-decade trends 2Health News:Drug use increasingly glamorized in rap music, according to new study of 2-decade trends 3Health News:Normal Weight Doesn't Always Equal Healthy Weight 2Health News:Normal Weight Doesn't Always Equal Healthy Weight 3Health News:Whole Foods Market(R) Announces Eco-Conscious Youth Hosts for 'Whole Earth Generation(TM)' Show 2Health News:Whole Foods Market(R) Announces Eco-Conscious Youth Hosts for 'Whole Earth Generation(TM)' Show 3Health News:Whole Foods Market(R) Announces Eco-Conscious Youth Hosts for 'Whole Earth Generation(TM)' Show 4Health News:Crannose(TM) Extra Strength Women's Health Formula Targets Urinary Tract Infections 2Health News:Labopharm Appeals FDA's Decision on Once-Daily Tramadol to Next Supervisory Level After Additional Analysis Supports Efficacy 2Health News:Labopharm Appeals FDA's Decision on Once-Daily Tramadol to Next Supervisory Level After Additional Analysis Supports Efficacy 3
Sub Pectoral Bra...
Bandeau Bra...
Post-Surgical compression garments...
... The Albumin Cobalt Binding (ACB®) Test ... Ischemia Modified Albumin (IMA®) by measuring the ... patient serum sample. First identified in the ... albumin comes in contact with ischemic tissue ...
Medicine Products: